This is a hypothesis that we will be testing in a major new national adjuvant trial, POETIC-A, in which patients with early ER+ breast cancer whose tumour continues to show high Ki67 expression after 2 weeks AI will be randomised to additional CDK4/6 inhibition or not. This evidence concerns the gene CDK4 and breast cancer.